dc.date.accessioned | 2017-06-26T14:00:02Z | |
dc.date.available | 2017-06-26T14:00:02Z | |
dc.date.created | 2016-11-04T12:27:17Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Sas-Chen, Aldema Aure, Miriam Ragle Leibovich, Limor Carvalho, Silvia Enuka, Yehoshua Körner, Cindy Polycarpou-Schwarz, Maria Lavi, Sara Nevo, Nava Kuznetsov, Yuri Yuan, Justin Azuaje, Francisco Ulitsky, Igor Diederichs, Sven Wiemann, Stefan Yakhini, Zohar Kristensen, Vessela N. Børresen-Dale, Anne-Lise Yarden, Yosef Sauer, Torill Geisler, Jürgen Hofvind, Solveig Bathen, Tone Frost Borgen, Elin Engebråten, Olav Fodstad, Øystein Garred, Øystein Geitvik, Gry Kåresen, Rolf Naume, Bjørn Mælandsmo, Gunhild Russnes, Hege Elisabeth Giercksky Schlichting, Ellen Sørlie, Therese Lingjærde, Ole Christian Sahlberg, Kristine Kleivi Skjerven, Helle Fritzman, Britt . LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Molecular Medicine. 2016, 8(9), 1052-1064 | |
dc.identifier.uri | http://hdl.handle.net/10852/55730 | |
dc.description.abstract | Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal‐like subtype associates with increased EGFR signaling, while another, the HER2‐enriched subtype, engages a kin of EGFR. Based on the premise that EGFR‐regulated lncRNAs might control the aggressiveness of basal‐like tumors, we identified multiple EGFR‐inducible lncRNAs in basal‐like normal cells and overlaid them with the transcriptomes of over 3,000 breast cancer patients. This led to the identification of 11 prognostic lncRNAs. Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal‐like and in HER2‐positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo. In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers. | en_US |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer | en_US |
dc.type | Journal article | en_US |
dc.creator.author | Sas-Chen, Aldema | |
dc.creator.author | Aure, Miriam Ragle | |
dc.creator.author | Leibovich, Limor | |
dc.creator.author | Carvalho, Silvia | |
dc.creator.author | Enuka, Yehoshua | |
dc.creator.author | Körner, Cindy | |
dc.creator.author | Polycarpou-Schwarz, Maria | |
dc.creator.author | Lavi, Sara | |
dc.creator.author | Nevo, Nava | |
dc.creator.author | Kuznetsov, Yuri | |
dc.creator.author | Yuan, Justin | |
dc.creator.author | Azuaje, Francisco | |
dc.creator.author | Ulitsky, Igor | |
dc.creator.author | Diederichs, Sven | |
dc.creator.author | Wiemann, Stefan | |
dc.creator.author | Yakhini, Zohar | |
dc.creator.author | Kristensen, Vessela N. | |
dc.creator.author | Børresen-Dale, Anne-Lise | |
dc.creator.author | Yarden, Yosef | |
dc.creator.author | Sauer, Torill | |
dc.creator.author | Geisler, Jürgen | |
dc.creator.author | Hofvind, Solveig | |
dc.creator.author | Bathen, Tone Frost | |
dc.creator.author | Borgen, Elin | |
dc.creator.author | Engebråten, Olav | |
dc.creator.author | Fodstad, Øystein | |
dc.creator.author | Garred, Øystein | |
dc.creator.author | Geitvik, Gry | |
dc.creator.author | Kåresen, Rolf | |
dc.creator.author | Naume, Bjørn | |
dc.creator.author | Mælandsmo, Gunhild | |
dc.creator.author | Russnes, Hege Elisabeth Giercksky | |
dc.creator.author | Schlichting, Ellen | |
dc.creator.author | Sørlie, Therese | |
dc.creator.author | Lingjærde, Ole Christian | |
dc.creator.author | Sahlberg, Kristine Kleivi | |
dc.creator.author | Skjerven, Helle | |
dc.creator.author | Fritzman, Britt | |
cristin.unitcode | 185,53,49,0 | |
cristin.unitname | Kreftklinikken | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 1397340 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EMBO Molecular Medicine&rft.volume=8&rft.spage=1052&rft.date=2016 | |
dc.identifier.jtitle | EMBO Molecular Medicine | |
dc.identifier.volume | 8 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 1052 | |
dc.identifier.endpage | 1064 | |
dc.identifier.doi | http://dx.doi.org/10.15252/emmm.201606198 | |
dc.identifier.urn | URN:NBN:no-58496 | |
dc.type.document | Tidsskriftartikkel | en_US |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1757-4676 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/55730/1/1052.full.pdf | |
dc.type.version | PublishedVersion | |